Evidence map›Paper›PMID 28711716›Full record

ArticleCellular signalling2017

Impact of paroxetine on proximal β-adrenergic receptor signaling.

Shuchi Guo, Rhonda L Carter, Laurel A Grisanti, Walter J Koch, Douglas G Tilley

Open access · greenAbstract read
In one paragraph

Article in Cellular signalling, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. G protein-coupled receptor kinases in hypertension: physiology, pathogenesis, and therapeutic targets.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
  3. GRK2 in cardiovascular disease and its potential as a therapeutic target.Journal of molecular and cellular cardiology · 2022
    Review
  4. Article
  5. Targeting G protein-coupled receptor kinases (GRKs) to G protein-coupled receptors.Current opinion in endocrine and metabolic research · 2021
    Article
  6. Article
  7. Review
  8. Review
  9. S1PBioscience reports · 2018
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shuchi GuoCenter for Translational Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Rhonda L CarterCenter for Translational Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Laurel A GrisantiCenter for Translational Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Walter J KochCenter for Translational Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Douglas G TilleyCenter for Translational Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. Electronic address: douglas.tilley@temple.edu.
Temple University · US

Funding

Targeted Cancer Therapeutics and Heart Failure: Mechanisms and Post-injury RepairP01HL091799 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI KOCH, WALTER J. · 2008 to 2018
$23.1M
Targeting GRK2 in the HeartR01HL061690 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI KOCH, WALTER J. · 1998 to 2022
$4.2M
Targeting GRK2 (BARK1) in Heart FailureR37HL061690 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI KOCH, WALTER J. · 2009 to 2018
$3.9M
Molecular Mechanisms of Cardiac beta1AR-EGFR Association and SignalingR01HL105414 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI TILLEY, DOUGLAS · 2011 to 2019
$3.4M
NHLBI NIH HHS P01 HL091799NHLBI NIH HHS R01 HL061690NHLBI NIH HHS R01 HL105414NHLBI NIH HHS R37 HL061690
6 · The paper itself

Abstract

β-adrenergic receptors (βAR) regulate numerous functions throughout the body, however G protein-coupled receptor kinase (GRK)-dependent desensitization of βAR has long been recognized as a maladaptive process in the progression of various disease states. Thus, the development of small molecule inhibitors of GRKs for the study of these processes and as potential therapeutics has been at the forefront of recent research efforts. Via structural and biochemical analyses, the selective serotonin reuptake inhibitor (SSRI) paroxetine was identified as a GRK2 inhibitor that enhances βAR-dependent cardiomyocyte and cardiac contractility and reverses cardiac dysfunction and myocardial βAR expression in mouse models of heart failure. Despite these functional outcomes, consistent with diminished βAR desensitization, the proximal βAR signaling mechanisms sensitive to paroxetine have not been reported. In this study, we aimed to determine whether paroxetine prevents classic βAR desensitization-related signaling mechanisms at a molecular level. Therefore, via immunoblotting, radioligand binding, fluorescence resonance energy transfer (FRET) and microscopy assays, we have performed an assessment of the effect of paroxetine on proximal βAR signaling responses. Indeed, paroxetine treatment inhibited ligand-induced β2AR phosphorylation in a concentration-dependent manner. Additionally, for both β1AR and β2AR, paroxetine decreased ligand-induced βarrestin2 recruitment and subsequent receptor internalization. Thus, paroxetine inhibits βAR desensitization mechanisms consistent with GRK2 inhibition and provides a useful pharmacological tool for studying these proximal GPCR signaling responses.

Indexed as

Signal TransductionAdrenergic beta-Agonistsbeta-Arrestin 2Cell LineEndocytosisHumansParoxetinePhosphorylationReceptors, Adrenergic, betaAdrenergic beta-Agonistsbeta-Arrestin 2ParoxetineReceptors, Adrenergic, betaG protein-coupled receptor kinaseParoxetineβ-adrenergic receptorβ-arrestin

Identifiers

PMID28711716
PMCPMC5646168
OpenAlexW2734673299

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.